MedTrace Logo

COL-3 in Treating Patients With Progressive or Recurrent Brain Tumors

NCT00004147 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2013-06-21

No results posted yet for this study

Summary

RATIONALE: COL-3 may stop the growth of brain tumors by stopping blood flow to the tumor.

PURPOSE: Phase I/II trial to study the effectiveness of COL-3 in treating patients who have progressive or recurrent brain tumors following radiation therapy or chemotherapy.

Conditions

Interventions

DRUG

incyclinide

Sponsors & Collaborators

  • New Approaches to Brain Tumor Therapy Consortium

    lead OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

Principal Investigators

  • Pamela Z. New, MD · The University of Texas Health Science Center at San Antonio

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31
Completion
2006-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004147 on ClinicalTrials.gov